reporting on earnings. a fantastic by revenues. with earnings with and Within QX quarterly $X.X closed record call. record tremendous congratulating non-GAAP revenues including revenues and fiscal to XXXX. this, Kim, you, our drove like I'd today's record CooperSurgical was CooperVision Thank to both welcome, margins year billion, of record improving all-time also This that everyone, start a employees and
innovative on focus products capacity, and our in XXXX strategic our state-of-the-art investing with increasing on We've our including entered taking expanding new a priorities, technology and executing our profitability manufacturing share, now launching and fiscal products, of our driving developing availability investments, people. optimizing the
into getting on and high-level QX XXXX. fiscal provide me comments details, some Before let the
CooperVision led led silicone dailies at than PARAGARD a softness end and expected. quarter, offset by by torics had the main had unexpected a of QX, being by full of in multifocals, growth For suite solid in in with double-digit fertility, also solid hydrogel quarter. strength QX, our decline and a CooperSurgical offset the greater the
or driving with our -- sorry, strong investment improved I'm P&L prior and activity earnings QX Our margin growth. improvements
X% X.X%. to XXXX, us ongoing around a Moving of coming lens constant to market Price and, taking us, the in X% variety with myopia from with dailies to into fiscal the inflation, the share contact items, growth we X/X should including in in growing rest wearers growing and offset forecast torics growth growth, management. trade-up currency supporting for the of multifocals, in X.X% growth
remainder of For mid-single in low business growth reporting the the fertility single-digit the we with CooperSurgical, high growth and posting organic growth. single-digit digits expect
share CooperSurgical share earnings organically, growing X% $X.XXX $XXX X% up details. our $XXX of by strength or revenues XX% portfolio. X% Non-GAAP year-over-year to or led fertility organically. Consolidated throughout billion, per or or of reported including were product quarterly quarterly up X% to organically. posted QX Moving up XX% up revenues grew XX% million, revenues million, up organically, CooperVision $X.XX. XX% XX% market-leading significant taking
data remaining our very lens extended For #X new as world the in the CooperVision, wearers company with our we position in of healthy. contact terms fit
dailies, basis, and revenue X%, with Asia Pac, strength EMEA, by a torics driven multifocals in X%. on XX%; growing share and the gained also We Americas
hydrogel silicone spheres myopia management and torics our our with Avaira our daily categories, clariti and XX% silicone X%, multifocals hydrogel up business grew grew X% X% and lenses and Within grew FRP and X%. Biofinity lenses, grew grew MyDay modalities, and MiSight Within XX%.
particular, to forward our lifestyle daily MyDay an the in growth and led specifically U.S., with it. of lens multifocals. great digital across MyDay love hydrogel MyDay, hydrogel boost its patients full Energys premium technology Turning We the In way Energys today's innovative growth that and drove continuing. lenses. quarter. digital silicone torics posted daily another designed trend portfolio look we to offers spheres, for and strong silicone
continues in with advanced range. design, very toric multifocal system that across Meanwhile, North nicely or levels combination resulted America success high an paired MyDay with our has pairs do fit industry-leading Europe parameter including its a performing XX% And unique expansion well with rate less. easy satisfaction its is in and and SKU our to MyDay design an market-leading X of fitting
products, remains improving For expand and strong allow is capacity to all as demand these availability. the future bright us will
the upgraded during lenses and year. clariti strength multifocal momentum of easy known affordability, and their upgrading material. our the be into the are is and lens launch Moving which and comfort, wearers. is rest this seen hydrogel design fitting brings of This another the we'll wearers being in received U.S., our multifocal, highly also world to These quarter. MyDay launching the it We've resulting well this successful around had for handling new We legacy clariti. with in in solid
of these Speaking personal multifocals Both are experience. terrific products. from
multifocal lenses If you're yet, missing contact presbyopic and out. you're not wearing
XXs, then vision visual didn't got into and changer. until me, been reaching For crisp clear a Getting without for any need reading glasses has hit I correction me. it game I my
several offer happy choose that really from. So to I'm now outstanding multifocals we
Moving had Biofinity QX. to another and lenses. silicone in frequent Avaira quarter hydrogel strong replacement our
lens to see our both products. and have innovative especially platforms to market-leading consistent these with from and designs franchises manufacturing an moat, growth extended continue made-to-order effective and created of We ranges respect
We continue this performance our momentum. expect to given
seeing Regardless, around being strong around said, did contraction quarter, results. that grow comfortable that depressed positive That world, remain we it will trends to similar and myopia XXXX, in momentum. MiSight U.S. revenue fiscal to in given the the XX% this activity we're benefiting October remained fitting fitting from what second MiSight year. was highest the inventory October Moving back-to-school management. in ever, month our
Regarding national concluded the and fit successful These myopia campaigns media benefits very resulted MiSight. about and a markets, significant in proactive Pacific campaigns activity. the parents were in educating in of being and treatment. Asia We of U.S. targeted children number just
management We and Pediatric evidence in also Korea, Korean gold Pacific showcased clinical clinical scientific in Ophthalmology annual with Myopia insights the International symposium Asia our at Association and standard on extensive interventions. the Conference global leadership of at myopia deliver China partnering to XXXX our
Optometric U.S., momentum, media gain collective seminars our the Association the creating visibility and through to considerable myopia In partnership continues at interviews, conferences. presentations American with
revenues activity, CooperSurgical. of We to consumables, or to services, genetic forward million, donor be up million, leading Moving Within driven equipment, testing X% posted organically. products or innovative by $XXX up and reported XX% including capital we're to up our revenues reproductive Fertility portfolio drive fertility and XX% portfolio up this, our $XXX continues continuing and XX% of of innovation. organically. quarterly with
This and the at capabilities. Medicine was Conference, presentations meetings American leading highlighted recent which genomics Society our Reproductive on of featured
offering healthy detect the improve baby. having suite an insights that on were excited in to and testing the likelihood company we intelligence variations fertility of present forefront our build DNA will learning the level, to to embryo a at updates machine methods, of statistical being providing As genetic tests artificial developed further
professionals We and trained a for Society lab, technologists embryology need of and Reproductive the program also newly in growing groundbreaking fertility national training its clinical with the a highly ASRM formed more collaboration space. for announced learning biologists a first support kind for to the
due strong by The X and childbirth, the awareness, estimates factors. World The expand, in Health technology. macro These improving X Regarding a to trends. their worldwide women global benefits coverage treatment, of fertility Organization broader continues driven that include industry. to increasing underlying point some patient to infertility will growth at variety access experience improving in people health market delaying increasing lives
this is a industry So potential. growth that offers significant long-term large
leader a addressing and committed deeply critical by space, remain improving the birth access rates. driving clinics of innovation, As care in challenges to supporting to global and declining the we patients
geographically continuing most be the focus Our into providing products we'll XXXX, efforts. expanding is new advancing R&D and solutions where training, advanced and offering services, extensive clinical on launching our
We driven million, of Cook the assets strategic the year Office by beginning successful the obp and more acquisitions certain to $XXX posted Medical year-over-year, Surgical. of sales XX% and at Surgical. up of Moving recently,
were surgical deals, organically. sales office flat and these Excluding
offset Our uteri delivered Ally we from by birth invasive solid minimally weaker Medical manipulator portfolio XX% Devices which was control and was than in a delivery our led as decline labor feel by gynecological growth other our the pressure products, options. to surgical expected this continue as but such our portfolio of Paragard, in devices
trajectory. to diversified expect system portfolio that coming with year leverage revenue successful year work. reap growth prior of growth new in We as puts benefits investment better integration our products, system, a some upgrade our launch wrap With To margin solid is and but IT this we products and services, activity our CooperSurgical. of and the our improvements and great of we continue had now much up position this the us U.S. QX stable challenges
made We over was record the and this turn significant to expansion, I advancements our Before operational year in and capacity Brian, for revenues improvements great throughout development. investing call reported organization, a Cooper. employee say let me
reporting to objectives enter long-range on to we forward continuing we're year. fiscal our strategic execute looking As XXXX, and strong another
call the over with to Brian. And turn that, I'll